DK1343523T3 - Use of activated factor VII for the treatment of thrombolytic therapy-induced severe bleeding - Google Patents

Use of activated factor VII for the treatment of thrombolytic therapy-induced severe bleeding

Info

Publication number
DK1343523T3
DK1343523T3 DK01995705T DK01995705T DK1343523T3 DK 1343523 T3 DK1343523 T3 DK 1343523T3 DK 01995705 T DK01995705 T DK 01995705T DK 01995705 T DK01995705 T DK 01995705T DK 1343523 T3 DK1343523 T3 DK 1343523T3
Authority
DK
Denmark
Prior art keywords
factor vii
treatment
activated factor
thrombolytic therapy
severe bleeding
Prior art date
Application number
DK01995705T
Other languages
Danish (da)
Inventor
Gerhard Heusel
Cord Skamira
Jean Marie Stassen
Wolfgang Wienen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1343523T3 publication Critical patent/DK1343523T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Major bleedings induced by thrombolytic/fibrinolytic therapy, including intracranial haemorrhages, are treated by administering to a subject suffering from such bleedings an effective amount of activated coagulation factor VII (VIIa) or of a functional derivative thereof.
DK01995705T 2000-12-21 2001-12-20 Use of activated factor VII for the treatment of thrombolytic therapy-induced severe bleeding DK1343523T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00128252A EP1216709A1 (en) 2000-12-21 2000-12-21 Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings
PCT/EP2001/015132 WO2002049665A2 (en) 2000-12-21 2001-12-20 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings

Publications (1)

Publication Number Publication Date
DK1343523T3 true DK1343523T3 (en) 2007-04-10

Family

ID=8170769

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01995705T DK1343523T3 (en) 2000-12-21 2001-12-20 Use of activated factor VII for the treatment of thrombolytic therapy-induced severe bleeding

Country Status (25)

Country Link
US (2) US20040087502A1 (en)
EP (2) EP1216709A1 (en)
JP (1) JP2004516273A (en)
KR (1) KR20030063454A (en)
CN (1) CN1482919A (en)
AT (1) ATE353666T1 (en)
AU (2) AU2638602A (en)
BR (1) BR0116151A (en)
CA (1) CA2431986A1 (en)
CY (1) CY1106363T1 (en)
CZ (1) CZ300670B6 (en)
DE (1) DE60126650T2 (en)
DK (1) DK1343523T3 (en)
EC (1) ECSP034647A (en)
ES (1) ES2280429T3 (en)
HU (1) HUP0302574A3 (en)
IL (1) IL155886A0 (en)
MX (1) MXPA03005641A (en)
NZ (1) NZ549850A (en)
PL (1) PL205878B1 (en)
PT (1) PT1343523E (en)
RU (1) RU2286796C2 (en)
SI (1) SI1343523T1 (en)
WO (1) WO2002049665A2 (en)
ZA (1) ZA200304140B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512316A (en) * 2004-06-21 2008-02-26 Novo Nordisk Healthcare Ag methods for preventing or alleviating one or more complications of intracerebral hemorrhage and for preventing or alleviating one or more complications of ich in a majority of ich patients, and use of a first coagulation agent.
WO2007009895A2 (en) * 2005-07-15 2007-01-25 Novo Nordisk Health Care Ag USE OF FACTOR VIIa OR FACTOR VIIa EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN PATIENTS TREATED WITH ANTIPLATELET THERAPY
JP2011509978A (en) 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー Use of Factor VIIa or Factor VIIa equivalent to prevent or attenuate bleeding expansion and / or edema formation after intracerebral hemorrhage (ICH) in selected ICH patient subpopulations
RU2552339C1 (en) * 2014-02-19 2015-06-10 Общество с ограниченной ответственностью фирма "Технология-Стандарт" Method of preventing bleeding caused by use of streptokinase in experiment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function

Also Published As

Publication number Publication date
RU2003122362A (en) 2005-02-10
WO2002049665A2 (en) 2002-06-27
EP1216709A1 (en) 2002-06-26
RU2286796C2 (en) 2006-11-10
MXPA03005641A (en) 2004-12-03
CZ20031743A3 (en) 2003-11-12
CZ300670B6 (en) 2009-07-15
EP1343523B1 (en) 2007-02-14
CA2431986A1 (en) 2002-06-27
PT1343523E (en) 2007-03-30
IL155886A0 (en) 2003-12-23
US20040087502A1 (en) 2004-05-06
PL205878B1 (en) 2010-06-30
ATE353666T1 (en) 2007-03-15
SI1343523T1 (en) 2007-04-30
BR0116151A (en) 2003-10-21
AU2638602A (en) 2002-07-01
DE60126650D1 (en) 2007-03-29
ES2280429T3 (en) 2007-09-16
KR20030063454A (en) 2003-07-28
PL361855A1 (en) 2004-10-04
JP2004516273A (en) 2004-06-03
NZ549850A (en) 2008-04-30
US20080286259A1 (en) 2008-11-20
EP1343523A2 (en) 2003-09-17
CN1482919A (en) 2004-03-17
ECSP034647A (en) 2003-07-25
ZA200304140B (en) 2004-04-22
HUP0302574A3 (en) 2010-01-28
HUP0302574A2 (en) 2003-10-28
DE60126650T2 (en) 2007-10-31
CY1106363T1 (en) 2011-10-12
AU2002226386B2 (en) 2005-12-22
WO2002049665A3 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
DK1414494T3 (en) Inhibitory antibodies of HER3 activity
CY1107054T1 (en) KINAZOLIN SOLUTION BITS
EA200200306A1 (en) TRYCYCLIC INHIBITORS POLY (ADP-Ribozo) Polymerase
DE50310516D1 (en) Fredericamycin DERIVATIVES
NL300385I1 (en) Synergistic combinations including a renin inhibitor for cardiovascular diseases.
ATE380029T1 (en) GABA ANALOG PRODRUGS, COMPOSITIONS AND THEIR USES
NO20034204L (en) Pharmaceutical combinations for the treatment of cancer
DK1411938T3 (en) Use of cyclopamine in the manufacture of a medicament for the treatment of psoriasis
AU2406402A (en) Substituted benzene derivatives or salts thereof
BR9708114A (en) Xanthone analogues for the treatment of infectious diseases.
ATE319439T1 (en) AGENTS FOR THE TREATMENT OF DISEASES OF THE TRACHEO-BRONCHIAL TRACT, IN PARTICULAR COPD
DE60332387D1 (en) ALPHA-2-DELTA LIGAND FOR THE TREATMENT OF LOWER HARNESS SYMPTOMS
ATE456377T1 (en) TREATMENT OF METASTASIC CARCINOMA OF THE KIDNEY
DK1343523T3 (en) Use of activated factor VII for the treatment of thrombolytic therapy-induced severe bleeding
NO20032406L (en) Use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of urinary incontinence
EE200300213A (en) Use of SARP-1 for the treatment and / or prevention of scleroderma
EA200301299A1 (en) THE USE OF IL-18 INHIBITORS FOR THE TREATMENT AND PREVENTION OF CNS DAMAGE
IT1320192B1 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PSORIASIS.
ATE415165T1 (en) COMBINED TUMOR THERAPY BASED ON DISTAMYCIN-ACRYLOYL DERIVATIVES AND ANTIMETABOLIC AGENTS
DE602004009166D1 (en) New analogues of nitrobenzylthioinosine
DK1332229T3 (en) Method of screening for the treatment of obesity
DE60034580D1 (en) PEPTIDE FOR THE TREATMENT OF NERVE DISEASES